Atenolol as primary therapy in previously untreated hypertensives and as an adjuvant to other therapy. A South African Multicentre Study.
A series of 50 previously untreated hypertensives (group A) were treated with atenolol 100 mg daily and matching placebo in a double-blind cross-over study. A series of 60 hypertensives who were poorly controlled on non-beta-adrenergic receptor blocking drugs, as evidenced by a diastolic blood pressure of between 100 and 120 mmHg inclusive (group B), were treated in the same manner as group A except that they continued to take their previous non-beta-adrenergic receptor blocking drugs throughout the trial. The large majority of patients in both groups (95% and 72%) experienced a fall in blood pressure to satisfactory levels with no significant additional side-effects when compared with placebo treatment.
D000277:Adjuvants, Pharmaceutic; D000328:Adult; D001262:Atenolol / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011412:Propanolamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects
D000277:Adjuvants, Pharmaceutic; D010919:Placebos; D011412:Propanolamines; D001262:Atenolol